Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795791 | 1.00 | CYP3A4 (0.39) | CYP3A4ALDH1A1LMNAHTTMEN1 | |
| SCHEMBL2750503 | 0.92 | ALDH1A1 (0.40) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL30794740 | 0.91 | ALDH1A1 (0.39) | CYP3A4ALDH1A1LMNAHTTMEN1 | |
| SCHEMBL2749696 | 0.91 | ALDH1A1 (0.39) | CYP3A4ALDH1A1LMNAHTTMEN1 | |
| SCHEMBL30794490 | 0.89 | ALDH1A1 (0.46) | CYP3A4ALDH1A1LMNAHTTMEN1 | |
| SCHEMBL2751560 | 0.89 | ALDH1A1 (0.46) | CYP3A4ALDH1A1LMNAHTTMEN1 | |
| SCHEMBL2751205 | 0.87 | ALDH1A1 (0.50) | CYP3A4ALDH1A1LMNAHTTMEN1 | |
| SCHEMBL30796035 | 0.87 | ALDH1A1 (0.50) | CYP3A4ALDH1A1LMNAHTTMEN1 | |
| SCHEMBL2750762 | 0.87 | KDM1A (0.38) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL30795050 | 0.87 | KDM1A (0.38) | ALDH1A1LMNAHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2465504-A1 | Novel 2,3-diamino-quinazolinone derivatives and their medical use | NeuroSearch A/S (DK) | 2012-06-20 | — | — | EP | claimed |
| US-8178544-B2 | 2, 3-diamino-quinazolinone derivatives and their medical use | NEUROSEARCH A/S (DK) | 2012-05-15 | — | — | US | claimed |
| US-20100160315-A1 | NOVEL 2, 3-DIAMINO-QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | NEURO SEARCH A/S (DK) | 2010-06-24 | — | — | US | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-2465504-A1 | Novel 2,3-diamino-quinazolinone derivatives and their medical use | NeuroSearch A/S (DK) | 2012-06-20 | — | — | EP | disclosed |
| US-8178544-B2 | 2, 3-diamino-quinazolinone derivatives and their medical use | NEUROSEARCH A/S (DK) | 2012-05-15 | — | — | US | disclosed |
| US-20100160315-A1 | NOVEL 2, 3-DIAMINO-QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | NEURO SEARCH A/S (DK) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160315-A1 | NOVEL 2, 3-DIAMINO-QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | KCNJ2, KCNN3, KCNK17 | CYP3A4 2860/4885ALDH1A1 1660/4885LMNA 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.